The bill aims to enhance access to prescription hormone therapy for patients of all ages by mandating that health plans provide reimbursement for a 12-month supply of such therapy when obtained at one time. Effective January 1, 2026, health plans that cover prescription hormone therapy must comply with this requirement, unless the enrollee requests a smaller supply, the prescribing provider specifies a smaller amount, or the therapy is classified as a controlled substance. The bill also stipulates that the 12-month refill requirement applies only to hormone therapies that can be safely stored at room temperature. For controlled substances, health plans must reimburse for the maximum refill allowed under state and federal law.

Additionally, the bill includes provisions that allow health plans to limit refills in the last quarter of the plan year if a 12-month supply has already been dispensed, and it permits prescribing providers to temporarily restrict refills to a 90-day supply during acute shortages. The bill also clarifies that health plans may apply drug utilization management strategies to the covered prescription drugs, and it defines "prescription hormone therapy" as FDA-approved drugs used to manage hormone levels, excluding certain medications like glucagon-like peptide-1 and its receptor agonists. The bill reenacts and amends existing law to incorporate these new requirements.